Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: AstraZeneca AB, SE-151 85 Södertälje, Sweden
Lynparza 100 mg film-coated tablets.
Lynparza 150 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Lynparza 100 mg film-coated tablets: Yellow to dark yellow, oval, bi-convex tablet, debossed with ‘OP100’ on one side and plain on the other side. Lynparza 150 mg film-coated tablets: Green to green/grey, oval, bi-convex tablet, debossed with ‘OP150’ on one side and plain on the other side. |
Lynparza 100 mg film-coated tablets: Each film-coated tablet contains 100 mg olaparib.
Lynparza 150 mg film-coated tablets: Each film-coated tablet contains 150 mg olaparib.
Excipient with known effect: This medicinal product contains 0.24 mg sodium per 100 mg tablet and 0.35 mg sodium per 150 mg tablet, i.e. essentially “sodium-free”.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Olaparib |
Olaparib is a potent inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP-2 and PARP-3), and has been shown to inhibit the growth of selected tumour cell lines in vitro and tumour growth in vivo either as a standalone treatment or in combination with established chemotherapies. |
| List of Excipients |
|---|
|
Tablet core: Copovidone Tablet coating: Hypromellose |
Alu/Alu non-perforated blister containing 8 film-coated tablets.
Pack sizes:
56 film-coated tablets (7 blisters).
Multipack containing 112 (2 packs of 56) film-coated tablets.
Not all pack sizes may be marketed.
AstraZeneca AB, SE-151 85 Södertälje, Sweden
EU/1/14/959/002
EU/1/14/959/003
EU/1/14/959/004
EU/1/14/959/005
Date of first authorisation: 16 December 2014
| Drug | Countries | |
|---|---|---|
| LYNPARZA | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
